Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19

doi:10.1111/bjh.16863

Case Reports

. 2020 Jul;190(2):e73-e76.

doi: 10.1111/bjh.16863. Epub 2020 Jun 4.

Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19

Santiago Thibaud¹, Douglas Tremblay¹, Sheena Bhalla¹, Brittney Zimmerman¹, Keith Sigel², Janice Gabrilove¹

Affiliations

¹ Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
² Division of Infectious Diseases, Icahn School of Medicine at Mount Sinaii, New York, NY, USA.

PMID: 32433778
PMCID: PMC7276870
DOI: 10.1111/bjh.16863

Case Reports

Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19

Santiago Thibaud et al. Br J Haematol. 2020 Jul.

. 2020 Jul;190(2):e73-e76.

doi: 10.1111/bjh.16863. Epub 2020 Jun 4.

Authors

Santiago Thibaud¹, Douglas Tremblay¹, Sheena Bhalla¹, Brittney Zimmerman¹, Keith Sigel², Janice Gabrilove¹

Affiliations

¹ Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
² Division of Infectious Diseases, Icahn School of Medicine at Mount Sinaii, New York, NY, USA.

PMID: 32433778
PMCID: PMC7276870
DOI: 10.1111/bjh.16863

No abstract available

Keywords: BTK inhibitors; CLL; COVID-19.

PubMed Disclaimer

Cited by

BTK inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): A Systematic Review.
Stack M, Sacco K, Castagnoli R, Livinski AA, Notarangelo LD, Lionakis MS. Stack M, et al. Res Sq [Preprint]. 2021 Mar 22:rs.3.rs-319342. doi: 10.21203/rs.3.rs-319342/v1. Res Sq. 2021. Update in: Clin Immunol. 2021 Sep;230:108816. doi: 10.1016/j.clim.2021.108816. PMID: 33791689 Free PMC article. Updated. Preprint.
Bruton's Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease.
Neys SFH, Rip J, Hendriks RW, Corneth OBJ. Neys SFH, et al. Drugs. 2021 Sep;81(14):1605-1626. doi: 10.1007/s40265-021-01592-0. Epub 2021 Oct 5. Drugs. 2021. PMID: 34609725 Free PMC article. Review.
A randomized, placebo-controlled trial of the BTK inhibitor zanubrutinib in hospitalized patients with COVID-19 respiratory distress: immune biomarker and clinical findings.
Treon SP, Kotton CN, Park DJ, Moranzoni G, Lemvigh CK, Gathe JC Jr, Varughese TA, Barnett CF, Belenchia JM, Clark NM, Farber CM, Abid MB, Ahmed G, Patterson CJ, Guerrera ML, Soumerai JD, Chea VA, Carulli IP, Southard J, Li S, Wu CJ, Livak KJ, Holmgren E, Kim P, Shi C, Lin H, Ramakrishnan V, Ou Y, Olszewski S, Olsen LR, Keskin DB, Hunter ZR, Tankersley C, Zimmerman T, Dhakal B. Treon SP, et al. Front Immunol. 2025 Jan 21;15:1369619. doi: 10.3389/fimmu.2024.1369619. eCollection 2024. Front Immunol. 2025. PMID: 39906744 Free PMC article. Clinical Trial.
COVID-19 among fit patients with CLL treated with venetoclax-based combinations.
Fürstenau M, Langerbeins P, De Silva N, Fink AM, Robrecht S, von Tresckow J, Simon F, Hohloch K, Droogendijk J, van der Klift M, van der Spek E, Illmer T, Schöttker B, Fischer K, Wendtner CM, Tausch E, Stilgenbauer S, Niemann CU, Gregor M, Kater AP, Hallek M, Eichhorst B. Fürstenau M, et al. Leukemia. 2020 Aug;34(8):2225-2229. doi: 10.1038/s41375-020-0941-7. Epub 2020 Jun 29. Leukemia. 2020. PMID: 32601378 Free PMC article. Clinical Trial. No abstract available.
Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9).
Cesaro S, Ljungman P, Mikulska M, Hirsch HH, von Lilienfeld-Toal M, Cordonnier C, Meylan S, Mehra V, Styczynski J, Marchesi F, Besson C, Baldanti F, Masculano RC, Beutel G, Einsele H, Azoulay E, Maertens J, de la Camara R; ECIL 9; Pagano L. Cesaro S, et al. Leukemia. 2022 Jun;36(6):1467-1480. doi: 10.1038/s41375-022-01578-1. Epub 2022 Apr 29. Leukemia. 2022. PMID: 35488021 Free PMC article. Review.

See all "Cited by" articles

References

1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. - PMC - PubMed
1. Niemann CU, Herman SE, Maric I, Gomez‐Rodriguez J, Biancotto A, Chang BY, et al. Disruption of in vivo Chronic Lymphocytic Leukemia Tumor‐Microenvironment Interactions by Ibrutinib‐Findings from an Investigator‐Initiated Phase II Study. Clin Cancer Res. 2016;22:1572–82. - PMC - PubMed
1. Florence JM, Krupa A, Booshehri LM, Davis SA, Matthay MA, Kurdowska AK. Inhibiting Bruton's tyrosine kinase rescues mice from lethal influenza‐induced acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2018;315:L52–L58. - PMC - PubMed
1. Yoshikawa T, Hill T, Li K, Peters CJ, Tseng CT. Severe acute respiratory syndrome (SARS) coronavirus‐induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte‐derived macrophages and dendritic cells. J Virol. 2009;83:3039–48. - PMC - PubMed
1. Treon SP, Castillo J, Skarbnik AP, Soumerai JD, Ghobrial IM, Guerrera ML, et al. The BTK‐inhibitor ibrutinib may protect against pulmonary injury in COVID‐19 infected patients. Blood. 2020;135:1912–5. - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

UL1 TR001433/TR/NCATS NIH HHS/United States

LinkOut - more resources

Full Text Sources

[1] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. - PMC - PubMed

[2] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. - PMC - PubMed

[3] Niemann CU, Herman SE, Maric I, Gomez‐Rodriguez J, Biancotto A, Chang BY, et al. Disruption of in vivo Chronic Lymphocytic Leukemia Tumor‐Microenvironment Interactions by Ibrutinib‐Findings from an Investigator‐Initiated Phase II Study. Clin Cancer Res. 2016;22:1572–82. - PMC - PubMed

[4] Niemann CU, Herman SE, Maric I, Gomez‐Rodriguez J, Biancotto A, Chang BY, et al. Disruption of in vivo Chronic Lymphocytic Leukemia Tumor‐Microenvironment Interactions by Ibrutinib‐Findings from an Investigator‐Initiated Phase II Study. Clin Cancer Res. 2016;22:1572–82. - PMC - PubMed

[5] Florence JM, Krupa A, Booshehri LM, Davis SA, Matthay MA, Kurdowska AK. Inhibiting Bruton's tyrosine kinase rescues mice from lethal influenza‐induced acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2018;315:L52–L58. - PMC - PubMed

[6] Florence JM, Krupa A, Booshehri LM, Davis SA, Matthay MA, Kurdowska AK. Inhibiting Bruton's tyrosine kinase rescues mice from lethal influenza‐induced acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2018;315:L52–L58. - PMC - PubMed

[7] Yoshikawa T, Hill T, Li K, Peters CJ, Tseng CT. Severe acute respiratory syndrome (SARS) coronavirus‐induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte‐derived macrophages and dendritic cells. J Virol. 2009;83:3039–48. - PMC - PubMed

[8] Yoshikawa T, Hill T, Li K, Peters CJ, Tseng CT. Severe acute respiratory syndrome (SARS) coronavirus‐induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte‐derived macrophages and dendritic cells. J Virol. 2009;83:3039–48. - PMC - PubMed

[9] Treon SP, Castillo J, Skarbnik AP, Soumerai JD, Ghobrial IM, Guerrera ML, et al. The BTK‐inhibitor ibrutinib may protect against pulmonary injury in COVID‐19 infected patients. Blood. 2020;135:1912–5. - PMC - PubMed

[10] Treon SP, Castillo J, Skarbnik AP, Soumerai JD, Ghobrial IM, Guerrera ML, et al. The BTK‐inhibitor ibrutinib may protect against pulmonary injury in COVID‐19 infected patients. Blood. 2020;135:1912–5. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19

Affiliations

Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19

Authors

Affiliations

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full Text Sources